Emerald Health Therapeutics Appoints Rebecca Wong as Vice President Quality Affairs

Source:  Emerald Health Therapeutics Inc.

Department head in quality assurance brings over 25 years’ pharmaceutical, biotechnology, and medical device industry experience to lead Emerald quality affairs strategy

Emerald Health Therapeutics Inc. (TSXV:EMH) (OTCQX:EMHTF) (“Emerald”) has appointed Rebecca Wong as Vice President Quality Affairs, with responsibility for quality systems at Emerald’s production and product development facilities. She will ensure Emerald’s systems and products meet Health Canada and international standards and implement traceability and accountability measures to uphold the Company’s commitment to high-quality cannabis products.

“Rebecca has worked exclusively in the rigorous environment of life sciences quality affairs and, impressively, has a flawless inspection record and exemplary reputation with regulators in Canada, the US, and worldwide,” said Chris Wagner, Chief Executive Officer of Emerald. “We believe her contributions to the team will strongly support Emerald’s mission to develop and manufacture value-added, pharmaceutical-grade cannabis products on a global scale.”  

Ms. Wong has over 25 years of managerial experience in quality assurance and quality control. She led multiple departments and established systems for vendor qualification, change control, deviations, risk analysis, equipment validation, compliance auditing, document management, and GxP training. Her responsibilities have encompassed quality systems implementation for production and testing, facility accreditation, and inspections in preclinical, clinical, and commercial phases for pharmaceuticals, genetically engineered products, and medical devices. 

Prior to joining Emerald, Ms. Wong was Executive Director of Quality Assurance at Novelion Therapeutics (formerly QLT Inc.), reporting to the CEO. She previously worked for life science companies including MDS Nordion, Cangene Corporation, and Biomira Inc. Ms. Wong earned a B.Sc. (Microbiology) from the University of Alberta. 

"I’m pleased to join a dynamic team that already has extensive hands-on experience in clinical research, GMP production practices, regulatory approval processes, and intellectual property creation,” said Ms. Wong. “Emerald has the scientific knowledge base to develop new innovative products and I look forward to applying my experience to further the company’s goal of producing high-quality cannabis products and advancing downstream product development.”

Ms. Wong has been granted an option to acquire up to 150,000 common shares priced at $5.69 vesting over 3 years. The option expires March 26, 2023.

Join us on our journey of making lives better through cannabis science.

About Emerald Health Therapeutics

Emerald Health Therapeutics (TSXV:EMH) (OTCQX:EMHTF) is a Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations and produces and sells dried cannabis and cannabis oil for medical purposes. It is adding a 500,000 ft² greenhouse in Metro Vancouver to serve the anticipated legal Canadian adult-use cannabis market starting in 2018. Emerald owns 50% of a joint venture with Village Farms International, Inc. that is converting an existing 1.1 million ft² greenhouse in Delta, BC to grow cannabis. Emerald’s team is highly experienced in life sciences, product development and large-scale agribusiness. The company is part of the Emerald Health Group, with multiple companies focused on developing the cannabis and cannabinoid products with potential wellness and medical benefits.